好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Decline in Cardiorespiratory Fitness Results in Increased Risk of Alzheimer's and Related Disorders
Aging, Dementia, and Behavioral Neurology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
9-013
To evaluate decline in cardiorespiratory fitness (CRF) and the risk of developing Alzheimer's Disease and Related Disorders (ADRD).
CRF and ADRD risk is inverse, independent, and graded.

We identified 75,851 Veterans without ADRD who completed at least three exercise tolerance tests (ETTs), two of which were at least one year apart. We conducted latent class growth analyses to cluster the trajectories of changes in age-adjusted CRF using all ETT data up to one year before first ADRD diagnosis. We selected the optimal number of classes using the Bayesian Information Criterion (BIC), the estimated average posterior probabilities of class membership in each trajectory class, with values >0.7 preferable, and interpretability of the solution. 

Unadjusted and adjusted Kaplan-Meier curves were plotted to evaluate the association between CRF trajectory cluster and survival probability of free-of-ADRD for different age groups.

Average number of ETTs was 18.7 (42.3), with the mean gap between first and last tests of 6.5 (3.8) years (range, 1.1 to 19.2) years. Five clusters of trajectories were identified: four stable groups differing in baseline fitness (groups 1-4), and one group (n=6,691) with substantial decline (>1.0 MET) from relatively high to low CRF level (group 5). Compared to group 4 (non-declining trajectory)  with similar baseline CRF as Group 5, the probability of ADRD-free survival was significantly lower for those in group 5. However,  Group 5 continued to perform better than the groups (groups 1 and 2) that had lower baseline and equivalent endpoint CRF.

These findings suggest a drop in CRF increases risk of ADRD and starting at a higher CRF confers protection, even after a decline. Prospective, longitudinal, biomarker-based research is needed.<div aju"="">
Authors/Disclosures
Edward Y. Zamrini, MD (Irvine Clinical Research)
PRESENTER
Dr. Zamrini has received personal compensation for serving as an employee of George Washington University. Dr. Zamrini has received personal compensation for serving as an employee of Irvine Clinical Research. Dr. Zamrini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NIH. Dr. Zamrini has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Zamrini has received research support from NIH. The institution of Dr. Zamrini has received research support from NIH.
Yan Cheng No disclosure on file
Peter Kokkinos (VA Medical Center) No disclosure on file
Charles Faselis No disclosure on file
Helen Sheriff (DC VAMC) No disclosure on file
Yijun Shao (George Washington University) No disclosure on file
Xuemei Sui (University of South Carolina) No disclosure on file
Ali Ahmed (DCVAMC) No disclosure on file
Qing Zeng-Treitler (George Washington University) No disclosure on file